ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2000
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended June 30, 2000. ResMed Inc. is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with over 600 employees and sells products in more than 50 countries. Principal manufacturing is located in Sydney, Australia, with executive offices in Poway, California.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2000 | Fiscal 1999 | Change |
|---|---|---|---|
| Net Revenues | $115,615 | $88,627 | +30.4% |
| Gross Profit | $78,624 | $59,211 | +32.8% |
| Gross Margin | 68.0% | 66.8% | +1.2 pts |
| Operating Income | $33,138 | $25,255 | +31.2% |
| Net Income | $22,226 | $16,102 | +38.0% |
| Diluted EPS | $0.69 | $0.52 | +32.7% |
| Operating Cash Flow | $20,275 | $18,188 | +11.5% |
| Working Capital | $47,550 | $32,529 | +46.2% |
| Long-Term Debt | $0 | $0 | - |
Note: The company had no long-term debt as of June 30, 2000. Cash and cash equivalents totaled $18.25 million, with an additional $3.71 million in marketable securities.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $27 million (30%) driven primarily by higher unit sales of flow generators and accessories in the Americas ($62.7M vs $51.0M) and Europe ($40.5M vs $30.2M).
- Margin Expansion: Gross margin improved to 68.0% from 66.8% due to manufacturing efficiencies, a decline in the Australian Dollar, and a shift toward higher-margin mask system sales.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 35% to $37.0 million, largely due to a 33% increase in sales and administrative personnel (from 212 to 281). R&D expenses increased 30% to $8.5 million.
- Foreign Exchange: Net foreign currency losses decreased significantly to $182,000 in 2000 compared to $2.5 million in 1999, improving "Other income (expense)" by $1.7 million.
- Acquisitions: The company acquired its Swedish distributor, Einar Egnell AB, for $576,000 in cash in January 2000.
Outlook, Risks, and Management Commentary
- Strategy: ResMed plans to continue product innovation (specifically AutoSet systems and improved masks), expand geographic presence, and increase public/clinical awareness of SDB. The company is also targeting new medical markets including stroke, congestive heart failure, and COPD.
- Liquidity: The company maintains strong liquidity with $22.0 million in cash and marketable securities. It has a $20 million revolving credit facility with Union Bank of California, of which $10 million was drawn in July 2000 to fund the purchase of its US headquarters.
- Key Risks:
- Reimbursement: Success depends on third-party payors (Medicare, private insurers) reimbursing patients. Changes in reimbursement policies or price controls could materially impact sales.
- Competition: The market is highly competitive with larger rivals (Respironics, DeVilbiss, Nellcor Puritan Bennett) that may have greater resources.
- Legal Proceedings: Ongoing patent litigation against Respironics (where summary judgments were granted against ResMed, pending appeal) and a new lawsuit against MPV Truma/Tiara Medical regarding mask design trademarks.
- Foreign Currency: Significant exposure to the Australian Dollar and Euro; fluctuations can negatively impact revenue and margins.
Investor Verification Checklist
- Reimbursement Trends: Verify current status of Medicare and private insurer reimbursement policies for CPAP/VPAP devices in the US and key European markets.
- Legal Outcomes: Monitor the status of the appeal regarding the Respironics patent infringement summary judgments and the outcome of the MPV Truma/Tiara lawsuit.
- Product Adoption: Assess market penetration rates for new products introduced in FY2000, specifically the S6 flow generator series and UltraMirage masks.
- Foreign Exchange Exposure: Review the effectiveness of the company's hedging program against the Australian Dollar given the significant portion of manufacturing costs incurred in AUD.
- Capital Allocation: Confirm the utilization of the $20 million credit facility and future capital expenditure plans for the new US facility and Oracle system implementation.